Using urinary proteins to predict blood pressure response in obese patients with hypertension
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
This study is testing whether certain proteins in urine can help predict how well obese patients with high blood pressure will respond to specific medications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 30 Years to 75 Years |
| Sex | All |
| Sponsor | Hippocration General Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Athens) |
| Trial ID | NCT06208072 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to identify specific peptides through urinary proteomic analysis that can predict how obese hypertensive patients will respond to treatments with irbesartan or eplerenone. The study addresses the challenge of uncontrolled hypertension by focusing on precision medicine, which tailors treatment based on individual variability. Participants will undergo a series of tests involving protein extraction and analysis to uncover potential biomarkers that could enhance treatment outcomes. The ultimate goal is to improve blood pressure management in this high-risk population.
Who should consider this trial
Good fit: Ideal candidates for this study are obese individuals with primary hypertension who have specific blood pressure readings and meet the inclusion criteria.
Not a fit: Patients with secondary hypertension, recent cardiovascular events, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for obese patients with hypertension.
How similar studies have performed: Previous small-scale studies have shown promise in using proteomic analysis to identify biomarkers, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Systolic office blood pressure 140-179mmHg and/or diastolic office blood pressure 90-119mmHg * Mean systolic 24h ABPM \>130mmHg and/or mean diastolic ABPM \>80mmHg * Obese patient with BMI 30-39.99kg/m2 * Signed informed consent Exclusion Criteria: * Participation in an Investigational Medicinal Product (IMP) or invasive device clinical trial during the study or in the last 6 months * Patient with secondary arterial hypertension * Patient with a history within 6 months of: Myocardial infarction, Unstable angina, Stroke * Patient with type 1 diabetes * Patient with systolic heart failure EF≤40% * Patient with chronic kidney disease (eGFR\<45mL/min/1.73m2) * Patient with bilateral renal artery stenosis * Patient with hyperkalemia (\>5.5 mEq/L) * Patient with hemodynamically significant valvular heart disease * Patient with Addison's disease * Female patient in pregnancy or caesarean section or female patient planning pregnancy. * Planned surgery or cardiovascular surgery in the next 6 months * Patient with absolute contraindication to any EDPS * Patient who needs to receive study medication for a different reason * Patient with neoplasia undergoing treatment (radiotherapy, chemotherapy, immunotherapy) * Patient with synchronous systemic disease with a survival expectancy less than the end of the study * Any condition that, in the judgment of the investigator, may adversely affect the efficacy and/or safety of the Investigational Medicinal Products (IEDs) (alcohol abuse, drug use, mental retardation) * Patient who has received treatment with systemic corticosteroids at least 3 months before joining the study * Patient receiving α-blockers with the exception of alfuzosin and tamsulosin for prostatic symptoms
Where this trial is running
Athens
- Hypertension Unit, A' University Cardiology Clinic, Hippocration General Hospital of Athens — Athens, Greece (Recruiting)
Study contacts
- Principal investigator: Konstantinos P Tsioufis, Prof — First University Cardiology Clinic, Hippocration General Hospital of Athens
- Study coordinator: Konstantinos P Tsioufis, Prof
- Email: ktsioufis@hippocratio.gr
- Phone: 6932586087
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.